1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

This article has no abstract
Epistemonikos ID: 93cd9715347e22a4e2fd6c9e61813842ca0171a6
First added on: Feb 15, 2025